<DOC>
	<DOC>NCT00313209</DOC>
	<brief_summary>The aim of the study is to compare the efficacy of roflumilast on pulmonary function and symptomatic parameters in patients with chronic obstructive pulmonary disease (COPD) during concomitant administration of salmeterol. The study duration will last up to 28 weeks. The study will provide further data on safety and tolerability of roflumilast.</brief_summary>
	<brief_title>Effect of Roflumilast on Lung Function in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Salmeterol: The EOS Study (BY217/M2-127)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Main History of COPD for at least 12 months prior to baseline visit FEV1/FVC ratio (postbronchodilator) ≤ 70% FEV1 (postbronchodilator) between ≥ 40% and ≤ 70% of predicted Main COPD exacerbation indicated by a treatment with systemic glucocorticosteroids and/or antibiotics not stopped at least 4 weeks prior to baseline visit</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Roflumilast</keyword>
	<keyword>Salmeterol</keyword>
	<keyword>COPD</keyword>
	<keyword>Chronic obstructive pulmonary disease</keyword>
</DOC>